• Our Company
  • Our Mission & Commitment
  • Key Facts
  • Leadership
  • Governance
  • History
  • Compliance & Ethics
  • Diversity & Inclusion
  • Our Websites
  • Achievements
  • Business Information
• R&D
  • R&D Strategy
  • In the Pipeline
  • Investigational Compound News
  • Disease Areas of Focus
  • Our R&D
  • Our Science
  • R&D Highlights
  • Major R&D Facilities
  • Clinical Trials
  • Investigator- Sponsored Research
• Products
  • Help Paying For Your Medicine
  • Counterfeit Drugs
  • Medical Information Inquiries
• News
  • Press Releases
  • Publications
  • Media Library
  • Key Facts
  • Leadership
  • Financial Reporting
  • Features
  • Achievements
  • Media Contacts
  • Subscribe to e-mail alerts
• Investors
  • Key Facts
  • Stock Information
  • SEC Filings
  • Financial Reporting
  • Events & Presentations
  • Shareholder Services
  • Investor Contacts
• Partnering
  • Why Partner With Us?
  • Areas of Interest
  • Our Process
  • Our Partners
  • Partnering News
  • Partnering Contact
• Responsibility
  • Bristol-Myers Squibb Foundation
  • Sustainability
  • Help Paying For Your Medicine
  • Building Our Communities
  • Grants & Giving
  • Position on Key Issues
  • Transparency
  • Clinical Trials
  • Combating Counterfeit Drugs
  • Disaster Relief & Product Donations
  • Achievements
  • Access to Medicines
• Careers
  • Job Opportunities
  • Our Culture
  • Diversity & Inclusion
  • Developing Our People
  • University Recruitment
  • Achievements
  • Benefits
  • Apply Now

BMS.com Home » Research » Investigational Compound News » Hepatitis C

Pipeline Asset Update for Daclatasvir (DCV; BMS-790052)
Discovered by Bristol-Myers Squibb through a genomics approach, daclatasvir, also known as BMS-790052 or DCV, is the first NS5A replication complex inhibitor to be investigated in hepatitis C clinical trials.
Conference on Retroviruses and Opportunistic Infections (CROI), 2012

BMS-790052 (NS5A inhibitor) and BMS-650032 (NS3 inhibitor)
BMS-790052 is an NS5A inhibitor and BMS-650032 is an NS3 protease inhibitor, both in development for the treatment of chronic hepatitis C virus (HCV) infection
American Association for the Study of Liver Diseases (AASLD), 2010

PEG-Interferon Lambda
A novel and potential first-in-class interferon in development for the treatment of hepatitis C virus (HCV) infection
American Association for the Study of Liver Diseases (AASLD), 2010

BMS-790052
Once-Daily NS5A Inhibitor Leads to High Rates of Extended Rapid Virologic Response in Treatment-Naïve HCV-Genotype 1 Subjects When Combined with Peginterferon and Ribavirin: A Phase 2a Trial
European Association for the Study of the Liver (EASL), April 2010